Merck to buy Idenix for about $3.85 billion
June 9 (Reuters) - Merck & Co Inc said it would buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion to complement its hepatitis C portfolio.
Merck will pay $24.50 per share in cash - more than three times Idenix's Friday closing price.
The companies said they expect the transaction to close in the third quarter. (Reporting by Natalie Grover in Bangalore; Editing by Maju Samuel)